ema prac semaglutide naion label update 2025 A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no Meeting highlights from the Pharmacovigilance
Description
doi: 10.2147/vhrm.s10952 [DOI] [PMC free article] [PubMed] [Google Scholar] 97.Palmer SC, Mavridis D, Nicolucci A, et al
Further research is warranted to confirm these findings in larger cohorts and explore semaglutide's longterm effects on iron homeostasis
Maintenance-phase tirzepatide use at stable weight carries substantially lower gallbladder risk than the active weight loss phase
Online, unfollow and mute anyone and anything that makes you feel less than
Never take metformin on an empty stomach, as this dramatically increases the chance of GI side effects
EBGM, empirical bayes geometric mean
